Skip to main content
Top
Published in: Tumor Biology 1/2016

01-01-2016 | Research Article

Genome-wide profiling of DNA methylation reveals preferred sequences of DNMTs in hepatocellular carcinoma cells

Authors: Hong Fan, Zhujiang Zhao, Yuchao Cheng, He Cui, Fengchang Qiao, Ling Wang, Jiaojiao Hu, Huzhang Wu, Wei Song

Published in: Tumor Biology | Issue 1/2016

Login to get access

Abstract

Aberrant DNA methylation of CpG site is among the earliest and most frequent alterations in developmental process and diseases including cancer. To elucidate the functional preferred site of DNMTs, we analyzed the feature of distinct methylated sequences and established the defined relationship between DNMTs and preference genomic DNA sequences. Small interfering RNA (siRNA) construct of DNTM1, DNMT3A, and DNMT3B was transfected into the human hepatocellular carcinoma cell line SMMC-7721, respectively. Distinguishing methylated fragments pool was enriched by SHH method in cells which is knocked down DNMT1, DNMT3A, DNMT3B, separately. The defined binding transcription factors (TFs) containing of 5′CpG islands were obtained with bioinformatics software and website. In SMMC-7721 hepatocellular carcinoma (HCC) cell line, DNMT1, DNMT3A, and DNMT3B were specific suppressed by their corresponding siRNA construct, separately. A 46, 42, 67 distinctive methylated fragments from three different DNMTs were evaluated according to genomic DNA database. Those separated fragments were distributed among genomic DNA regions of all chromosome complements, including coding genes, repeat sequences, and genes with unknown function. The majority of coding genes contain CpG islands in their promoter region. Cluster analysis demonstrated all of preference sequences identified by three DNMTs shares their own conserved sequences. In depleting of different DNMTs cells, 80 % of 103 upregulation genes induced by DNMT1 knock-down contain CpG sites; 76 % of 25 upregulation genes induced by DNMT3A knock-down contain CpG sites; 63 % of 126 upregulation genes induced by DNMT3B knock-down contain CpG sites. Our findings suggested that distinctive DNMTs targeted DNA methylation site to their preference sequences, and this targeting might be associated with diverse roles of DNMTs in tumorigenesis. Meanwhile, the analysis of preference sequences provides an alternative way to find out the individual function of DNMTs.
Appendix
Available only for authorised users
Literature
2.
go back to reference Jones PA. DNA methylation errors and cancer. Cancer Res. 1996;56:2463.PubMed Jones PA. DNA methylation errors and cancer. Cancer Res. 1996;56:2463.PubMed
3.
go back to reference Laird PW, Jackson-Grusby L, Fazeli A, Dickinson SL, Jung WE, Li E, et al. Suppression of intestinal neoplasia by DNA hypomethylation. Cell. 1995;81:197.CrossRefPubMed Laird PW, Jackson-Grusby L, Fazeli A, Dickinson SL, Jung WE, Li E, et al. Suppression of intestinal neoplasia by DNA hypomethylation. Cell. 1995;81:197.CrossRefPubMed
4.
go back to reference Dodge JE, Okano M, Dick F, Tsujimoto N, Chen T, Wang S, et al. Inactivation of Dnmt3b in mouse embryonic fibroblasts results in DNA hypomethylation, chromosomal instability, and spontaneous immortalization. J Biol Chem. 2005;280:17986–91.CrossRefPubMed Dodge JE, Okano M, Dick F, Tsujimoto N, Chen T, Wang S, et al. Inactivation of Dnmt3b in mouse embryonic fibroblasts results in DNA hypomethylation, chromosomal instability, and spontaneous immortalization. J Biol Chem. 2005;280:17986–91.CrossRefPubMed
5.
go back to reference Kaneda M, Okano M, Hata K, Sado T, Tsujimoto N, Li E, et al. Essential role for de novo DNA methyltransferase Dnmt3a in paternal and maternal imprinting. Nature. 2004;429:900–3.CrossRefPubMed Kaneda M, Okano M, Hata K, Sado T, Tsujimoto N, Li E, et al. Essential role for de novo DNA methyltransferase Dnmt3a in paternal and maternal imprinting. Nature. 2004;429:900–3.CrossRefPubMed
6.
go back to reference Okano M, Bell DW, Haber DA, Li E. DNA methyltransferases Dnmt3a and Dnmt3b are essential for de novo methylation and mammalian development. Cell. 1999;99:247–57.CrossRefPubMed Okano M, Bell DW, Haber DA, Li E. DNA methyltransferases Dnmt3a and Dnmt3b are essential for de novo methylation and mammalian development. Cell. 1999;99:247–57.CrossRefPubMed
8.
9.
go back to reference Lin C-H, Hsieh S-Y, Sheen I-S, Lee W-C, Chen T-C, Shyu W-C, et al. Genome-wide hypomethylation in hepatocellular carcinogenesis. Cancer Res. 2001;61:4238–43.PubMed Lin C-H, Hsieh S-Y, Sheen I-S, Lee W-C, Chen T-C, Shyu W-C, et al. Genome-wide hypomethylation in hepatocellular carcinogenesis. Cancer Res. 2001;61:4238–43.PubMed
10.
go back to reference Nishida N, Kudo M, Nagasaka T, Ikai I, Goel A. Characteristic patterns of altered DNA methylation predict emergence of human hepatocellular carcinoma. Hepatology. 2012;56(3):994–1003.CrossRefPubMed Nishida N, Kudo M, Nagasaka T, Ikai I, Goel A. Characteristic patterns of altered DNA methylation predict emergence of human hepatocellular carcinoma. Hepatology. 2012;56(3):994–1003.CrossRefPubMed
11.
go back to reference Shen J, Wang S, Zhang Y-J, Wu H-C, Kibriya MG, Jasmine F, et al. Exploring genome-wide DNA methylation profiles altered in hepatocellular carcinoma using infinium humanmethylation 450 beadchips. Epigenetics. 2013;8:1.CrossRef Shen J, Wang S, Zhang Y-J, Wu H-C, Kibriya MG, Jasmine F, et al. Exploring genome-wide DNA methylation profiles altered in hepatocellular carcinoma using infinium humanmethylation 450 beadchips. Epigenetics. 2013;8:1.CrossRef
12.
go back to reference Fernandez AFHC, Fraga MF. De novo DNA methyltransferases: Oncogenes, tumor suppressors, or both? Trends Genet. 2012;28:474–9.CrossRefPubMed Fernandez AFHC, Fraga MF. De novo DNA methyltransferases: Oncogenes, tumor suppressors, or both? Trends Genet. 2012;28:474–9.CrossRefPubMed
13.
14.
go back to reference Gruenbaum Y, Stein R, Cedar H, Razin A. Methylation of CpG sequences in eukaryotic DNA. FEBS Lett. 1981;124:67.15.CrossRef Gruenbaum Y, Stein R, Cedar H, Razin A. Methylation of CpG sequences in eukaryotic DNA. FEBS Lett. 1981;124:67.15.CrossRef
15.
go back to reference Razin A, Webb C, Szyf M, Yisraeli J, Rosenthal A, Naveh-Many T, et al. Variations in DNA methylation during mouse cell differentiation in vivo and in vitro. Proc Natl Acad Sci. 1984;81:2275–9.CrossRefPubMedPubMedCentral Razin A, Webb C, Szyf M, Yisraeli J, Rosenthal A, Naveh-Many T, et al. Variations in DNA methylation during mouse cell differentiation in vivo and in vitro. Proc Natl Acad Sci. 1984;81:2275–9.CrossRefPubMedPubMedCentral
18.
go back to reference Portela A, Esteller M. Epigenetic modifications and human disease. Nat Biotechnol. 2010;28:1057–68.CrossRefPubMed Portela A, Esteller M. Epigenetic modifications and human disease. Nat Biotechnol. 2010;28:1057–68.CrossRefPubMed
19.
go back to reference Handa V, Jeltsch A. Profound flanking sequence preference of Dnmt3a and Dnmt3b mammalian DNA methyltransferases shape the human epigenome. J Mol Biol. 2005;348:1103–12.CrossRefPubMed Handa V, Jeltsch A. Profound flanking sequence preference of Dnmt3a and Dnmt3b mammalian DNA methyltransferases shape the human epigenome. J Mol Biol. 2005;348:1103–12.CrossRefPubMed
21.
go back to reference Lander ES, Linton LM, Birren B, Nusbaum C, Zody MC, Baldwin J, et al. Initial sequencing and analysis of the human genome. Nature. 2001;409:860–921.CrossRefPubMed Lander ES, Linton LM, Birren B, Nusbaum C, Zody MC, Baldwin J, et al. Initial sequencing and analysis of the human genome. Nature. 2001;409:860–921.CrossRefPubMed
22.
go back to reference Venter JC, Adams MD, Myers EW, Li PW, Mural RJ, Sutton GG, et al. The sequence of the human genome. Science. 2001;291:1304–51.CrossRefPubMed Venter JC, Adams MD, Myers EW, Li PW, Mural RJ, Sutton GG, et al. The sequence of the human genome. Science. 2001;291:1304–51.CrossRefPubMed
23.
go back to reference Song J, Teplova M, Ishibe-Murakami S, Patel DJ. Structure-based mechanistic insights into DNMT1-mediated maintenance DNA methylation. Science. 2012;335:709–12.CrossRefPubMedPubMedCentral Song J, Teplova M, Ishibe-Murakami S, Patel DJ. Structure-based mechanistic insights into DNMT1-mediated maintenance DNA methylation. Science. 2012;335:709–12.CrossRefPubMedPubMedCentral
24.
go back to reference Reik W, Dean W, Walter J. Epigenetic reprogramming in mammalian development. Science. 2001;293:1089–93.CrossRefPubMed Reik W, Dean W, Walter J. Epigenetic reprogramming in mammalian development. Science. 2001;293:1089–93.CrossRefPubMed
25.
go back to reference Branco MR, Oda M, Reik W. Safeguarding parental identity: Dnmt1 maintains imprints during epigenetic reprogramming in early embryogenesis. Genes Dev. 2008;22:1567–71.CrossRefPubMedPubMedCentral Branco MR, Oda M, Reik W. Safeguarding parental identity: Dnmt1 maintains imprints during epigenetic reprogramming in early embryogenesis. Genes Dev. 2008;22:1567–71.CrossRefPubMedPubMedCentral
26.
go back to reference Wienholz BL, Kareta MS, Moarefi AH, Gordon CA, Ginno PA, Chédin F. DNMT3L modulates significant and distinct flanking sequence preference for DNA methylation by DNMT3A and DNMT3B in vivo. PLoS Genet. 2010;6:e1001106.CrossRefPubMedPubMedCentral Wienholz BL, Kareta MS, Moarefi AH, Gordon CA, Ginno PA, Chédin F. DNMT3L modulates significant and distinct flanking sequence preference for DNA methylation by DNMT3A and DNMT3B in vivo. PLoS Genet. 2010;6:e1001106.CrossRefPubMedPubMedCentral
27.
go back to reference Oka M, Rodić N, Graddy J, Chang L-J, Terada N. CpG sites preferentially methylated by Dnmt3a in vivo. J Biol Chem. 2006;281:9901–8.CrossRefPubMed Oka M, Rodić N, Graddy J, Chang L-J, Terada N. CpG sites preferentially methylated by Dnmt3a in vivo. J Biol Chem. 2006;281:9901–8.CrossRefPubMed
Metadata
Title
Genome-wide profiling of DNA methylation reveals preferred sequences of DNMTs in hepatocellular carcinoma cells
Authors
Hong Fan
Zhujiang Zhao
Yuchao Cheng
He Cui
Fengchang Qiao
Ling Wang
Jiaojiao Hu
Huzhang Wu
Wei Song
Publication date
01-01-2016
Publisher
Springer Netherlands
Published in
Tumor Biology / Issue 1/2016
Print ISSN: 1010-4283
Electronic ISSN: 1423-0380
DOI
https://doi.org/10.1007/s13277-015-3202-z

Other articles of this Issue 1/2016

Tumor Biology 1/2016 Go to the issue
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine